Recombinant staphylokinase (Supergene)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameRecombinant staphylokinase (Supergene)

Drug Alias NameGene modified staphylokinase - SupergeneFortelyzinForteplaseRecombinant staphylokinase variant - SupergeneRecombinant nonimmunogenic staphylokinase - Supergene

ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionPlasminogen stimulants

TargetsPlasminogen

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeIschemia +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesSupergene Llc

China Registration ClassN/A

Develop Information

Active CompaniesSupergene Llc

Inactive CompaniesN/A

Active IndicationsIschemic StrokeIschemiaPulmonary Embolism

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Myocardial Infarction

Other Information

ATC CodeN/A